(19)
(11) EP 3 284 519 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
18.04.2018 Bulletin 2018/16

(43) Date of publication:
21.02.2018 Bulletin 2018/08

(21) Application number: 17195276.5

(22) Date of filing: 28.04.2006
(51) International Patent Classification (IPC): 
A61P 31/18(2006.01)
C07D 498/04(2006.01)
 A61K 31/4985(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 28.04.2005 JP 2005131161
27.10.2005 JP 2005312076

(62) Application number of the earlier application in accordance with Art. 76 EPC:
16154531.4 / 3045206
12159079.8 / 2527007
06758843.4 / 1874117

(71) Applicants:
  • VIIV Healthcare Company
    Wilmington, DE 19808 (US)
  • Shionogi & Co., Ltd
    Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:
  • JOHNS, Brian Alvin
    Research Triangle Park, NC North Carolina 27709 (US)
  • KAWASUJI, Takashi
    Toyonaka, Osaka 561-0825 (JP)
  • TAISHI, Teruhiko
    Kita-ku, Osaka 530-0012 (JP)
  • TAODA, Yoshiyuki
    Toyonaka-shi, Osaka 561-0825 (JP)

(74) Representative: J A Kemp 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)

 
Remarks:
Amended claims in accordance with Rule 137(2) EPC.
Remarks:
This application was filed on 06-10-2017 as a divisional application to the application mentioned under INID code 62.
 


(54) POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY


(57) The present invention is to provide a novel compound (I-1) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof.

wherein
A ring is substituted ring of (a), (b) or (c)

wherein Z is O or NR19,
R19 is hydrogen, C1-10alkyl, C2-8alkenyl, C1-10alkylcarbonyl or C1-10alkylsulfonyl, and the other substituents on the A ring form a ring;
R14 and RX are hydrogen;
a broken line represents the presence or absence of a bond, provided that when the broken line represents the presence of a bond, RX is not present;
R1 is hydrogen or C1-10alkyl;
X is C1-6alkylene;
R2 is phenyl or phenyl substituted with at least halogen;
R3 is hydrogen, halogen, hydroxy, C1-10alkyl, C2-8alkenyl, C1-10alkoxy, C2-8alkenyloxy or amino;
or a pharmaceutically acceptable salt, or solvate thereof.